Mitochondrial Targeted Drug Delivery Combined with Manganese Catalyzed Fenton Reaction for the Treatment of Breast Cancer.

Xincheng Zhong,Xiaoyan Bao,Haiqing Zhong,Yi Zhou,Zhentao Zhang,Yiying Lu,Qi Dai,Qiyao Yang,Peng Ke,Yiyi Xia,Linjie Wu,Zaiyun Sui,Yan Lu,Min Han,WenHong Xu,Jianqing Gao
DOI: https://doi.org/10.1016/j.ijpharm.2022.121810
IF: 6.51
2022-01-01
International Journal of Pharmaceutics
Abstract:In previous studies, we found that triphenylphosphine-modified doxorubicin (TPP-DOX) can effectively kill drug-resistant tumor cells, but its effect on sensitive tumor cells is weakened. In this research, with albumin from Bovine Serum (BSA) as a carrier, TPP-DOX@MnBSA (TD@MB) nanoparticles were prepared by co-loading TPP-DOX and manganese which can realize the combination of chemotherapy and chemodynamic therapy (CDT). The uniform and stable nano-spherical nanoparticle can promote drug uptake, achieve mitochondrial-targeted drug delivery, increase intracellular reactive oxygen species (ROS) and catalyze the production of highly toxic oxidative hydroxyl radicals (OH·), further inhibiting the growth of both sensitive and drug-resistant MCF-7 cells. Besides, TD@MB can down-regulate the stemness-related proteins and the metastasis-related proteins, potentially decreasing the tumor stemness and metastasis. In vivo experiment indicated that TD@MB was able to exert desired antitumor effect, good tumor targeting and biocompatibility.
What problem does this paper attempt to address?